Altogether, accumulating evidence supports a role for IFN-γ and the Th17 axis in SLE, suggesting that severe manifestations, including LN, could benefit from IFN-γ- and/or Th17-blocking agents. This evidence concerns the gene IFNG and systemic lupus erythematosus.